



Dr. Reddy's Laboratories Ltd.
8-2-337, Road No. 3, Banjara Hills,
Hyderabad - 500 034, Telangana,
India.

CIN : L85195TG1984PLC004507

Tel : +91 40 4900 2900

Fax : +91 40 4900 2999

Email : mail@drreddys.com

www.drreddys.com

February 06, 2019

National Stock Exchange of India Ltd.
"Exchange Plaza"
Bandra-Kurla Complex, Bandra (East),
Mumbai – 400 051
Fax Nos.: 022-26598120/ 26598237/
26598238

Scrip Code: DRREDDY-EQ

Dear Sirs,

Ref.: Your email dated February 05, 2019

Sub: Clarification on news item appeared on Business Standard dated February 05, 2019 captioned 'US insurance firm names DRL in price-fixing complaint.'

This is with reference to your email dated February 05, 2019, seeking clarification on the above subject.

In this regard, please note that United Healthcare Services, Inc., filed a complaint against Dr. Reddy's Laboratories, Inc. (wholly owned subsidiary of Dr. Reddy's Laboratories Ltd.) and 42 other defendants, involving a total of 30 generic drugs, alleging an "overarching" price fixing conspiracy to rig bids and allocate customers with respect to 30 drugs.

The Complaint alleges violations of Section 1 of the Sherman Act, 15 U.S.C. §1, and violations of the Minnesota and 29 other States' antitrust laws, Minnesota's and 16 other States' Consumer Protection statutes, and claims of Unjust Enrichment, seeking injunctive relief, recovery of treble damages, punitive damages, attorney's fees and costs.


All cases related to Attorney Generals' law suits and certain private plaintiffs class action suits, including the above were consolidated in the multi district litigation as MDL-2724, *In re generics pharmaceuticals antitrust pricing litigation*.

The Company denies any wrongdoing and intends to vigorously defend against these claims. We believe that there is no material impact to the Company's operations or consolidated results.

The details of the above litigation has already been disclosed in our quarterly financial report on Form 6-K for the quarter ended December 31, 2018 filed with the US SEC and also submitted to NSE and BSE vide our letter dated February 02, 2019.

This is for your information and record.

With regards,


Sandeep Poddar
Company Secretary